EPS8L2

Across TCGA pan-cancer cohorts, EPS8L2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPS8L2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher EPS8L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EPS8L2 expression acts as an unfavorable survival marker.

ACC, UCEC, and HNSC are the cancer types where EPS8L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	3	view →
BLCA	DFS	Median	III,IV	0.121	0.488	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPS8L2–ACC (OS)

Open the ACC breakdown →